Work

Results of the Extension Trial of Optim, a Multicenter, Randomized Phase 3 Trial of Talimogene Laherparepvec (T-Vec) Vs Gm-Csf for Unresected Stage Iiib-Iv Melanoma

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu344.18

Authors: J.J. Nemunaitis, R.H. Andtbacka, M. Ross, T. Amatruda, J. Chesney, F.A. Collichio, K.J. Harrington, N.M. Steven, S. Fourie, L. Dreosti, A. Li, K. Liu, M. Shilkrut, R. Coffin, H. Kaufman

Institutions: Mary Crowley Cancer Research Center, University of Utah, Huntsman Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Louisville, University of North Carolina at Chapel Hill, Institute of Cancer Research, Royal Marsden Hospital, Queen Elizabeth Hospital Birmingham, Wellcome Trust, University of Pretoria, Amgen (United States), Rutgers Cancer Institute

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2307862673

FWCI: 0.644

Cites:

Cited by: 7

Related to: 10